Development of proprietary unique nM potent agonist of FPR/NOX2
for treatment of autoimmunity, inflammation and infections
ProNoxis focuses on the preclinical discovery of small-molecule drugs to treat chronic inflammation, autoimmunity and infections.
ProNoxis AB was founded in 2009 by LU Bioscience AB (LUBio), Karolinska Development AB, and Redoxis AB, as a Redoxis spin-off focusing on developing anti-inflammatory therapeutics targeting activation of the NADPH oxidase complex (NOX2).
Since 2012 it is wholly owned by Redoxis AB. Research and development are performed together with Redoxis AB and academic partners.